Anti-CD28 Monoclonal Antibody–Stimulated Cytokines Released from Blood Suppress CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes In Vitro
Open Access
- 1 January 2015
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43 (1) , 42-52
Abstract
Like most infections and certain inflammatory diseases, some therapeutic proteins cause a cytokine-mediated suppression of hepatic drug-metabolizing enzymes, which may lead to pharmacokinetic interactions with small molecule drugs. We propose a new in vitro method to evaluate the whole blood-mediated effects of therapeutic proteins on drug-metabolizing enzymes in human hepatocytes co-cultured with Kupffer cells. The traditional method involves treating hepatocyte co-cultures with the therapeutic protein, which detects hepatocyte and macrophage-mediated suppression of cytochrome P450. The new method involves treating whole human blood with a therapeutic protein to stimulate the release of cytokines from peripheral blood mononuclear cells (PBMC), after which plasma is prepared and added to the hepatocyte co-culture to evaluate cytochrome P450 enzyme expression. In this study, human blood was treated for 24 h at 37°C with bacterial lipopolysaccharide (LPS) or ANC28.1, an antibody against human T-cell receptor CD28. Cytokines were measured in plasma by sandwich immunoassay with electrochemiluminescense detection. Treatment of human hepatocyte co-cultures with LPS or with plasma from LPS-treated blood markedly reduced the expression of CYP1A2, CYP2B6 and CYP3A4. However, treatment of hepatocyte co-cultures with ANC28.1 did not suppress CYP expression but treatment with plasma from ANC28.1-treated blood suppressed CYP1A2, CYP2B6 and CYP3A4 activity and mRNA levels. The results demonstrated that applying plasma from human blood treated with a therapeutic protein to hepatocytes co-cultured with Kupffer cells is a suitable method to identify those therapeutic proteins that suppress CYP expression by an indirect mechanism, namely the release of cytokines from PBMC.Keywords
This publication has 45 references indexed in Scilit:
- Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokinesCurrent Opinion in Immunology, 2011
- AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical DevelopmentThe AAPS Journal, 2011
- Differential Role of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein in Toll-Like Receptor 2-Mediated Regulation of Gene Expression of Hepatic Cytokines and Drug-Metabolizing EnzymesDrug Metabolism and Disposition, 2011
- CYP-Mediated Therapeutic Protein-Drug InteractionsClinical Pharmacokinetics, 2010
- The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMCBritish Journal of Pharmacology, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- β2-Integrin-induced p38 MAPK Activation Is a Key Mediator in the CD14/TLR4/MD2-dependent Uptake of Lipopolysaccharide by HepatocytesJournal of Biological Chemistry, 2008
- Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic AntibodiesPLOS ONE, 2008
- Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human HepatocytesDrug Metabolism and Disposition, 2007
- A gene atlas of the mouse and human protein-encoding transcriptomesProceedings of the National Academy of Sciences, 2004